CN-122017251-A - Marker group for sarcopenia screening and diagnosis and application thereof

Abstract

The invention discloses a marker group for sarcopenia screening and diagnosis and application thereof, and belongs to the technical field of biological medicines. The marker panel consisted of CCL13, FGF2, fatty acid amide, and proline derivatives. The invention provides two myopathy high-sensitivity diagnosis combined models based on plasma multi-group combined machine learning. By Olink Explore 384 inflammatory proteome platform and LC-MS non-targeted metabolome technology, plasma samples of myopic patients and healthy controls were systematically analyzed to identify differentially expressed proteins and metabolites. And screening key features by adopting a plurality of machine learning algorithms, and constructing a single-group and double-group combined diagnosis model. A compact diagnostic model with only four core biomarkers developed therein, exhibited excellent diagnostic performance (AUC > 0.9) in independent validation cohorts, with high clinical conversion value.

Inventors

• JIANG HAO
• DONG BIRONG
• JIN HAORAN
• XU DONGQIN
• HUANG YANYAN

Assignees

• 四川大学华西医院

Dates

Publication Date

20260512

Application Date

20260209

Claims (9)

1. 1. A marker panel for use in sarcopenia screening and diagnosis, characterized by at least four proteins and metabolites selected from the group consisting of CXCL8, CCL13, IL18R1, ragcap 1L, CCL, FGF2, and CLEC4A; the metabolites include 1-(Cyclohexylmethyl)proline、24-epi-brassinolide、2-(3,4,5-Trimethoxyphenyl)-1H-benzimidazole、2(1H)-Pyrimidinone, 5-[3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-、Propentofylline、Adenosine and (3-Oxo-2-piperazinyl) ACETIC ACID.
2. 2. The set of markers according to claim 1, characterized in that the set of markers consists of two proteins and two metabolites.
3. 3. The set of markers of claim 1, wherein the set of markers consists of CCL13, FGF2, fatty acid amide, and proline derivatives.
4. 4. A set of markers according to claim 3, characterized in that the proline derivative is 1- (cyclohexylmethyl) proline.
5. 5. The set of markers of claim 1, wherein the set of markers consists of CXCL8、CCL13、IL18R1、RABGAP1L、CCL20、FGF2、CLEC4A、1-(Cyclohexylmethyl)proline、24-epi-brassinolide、2-(3,4,5-Trimethoxyphenyl)-1H-benzimidazole、2(1H)-Pyrimidinone, 5-[3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-、Propentofylline、Adenosine and (3-Oxo-2-piperazinyl) ACETIC ACID.
6. 6. A kit for screening and diagnosing sarcopenia, which comprises a reagent for detecting the marker set according to any one of claims 1 to 5.
7. 7. Use of a reagent for detecting a marker panel according to any one of claims 1 to 5 in the preparation of a formulation for screening and diagnosing sarcopenia.
8. 8. The use according to claim 7, wherein the formulation is a reagent, a kit or a test paper.
9. 9. The use according to claim 7, wherein the reagents comprise reagents for quantitative detection of protein antibodies and for quantitative detection of metabolites.

Description

Marker group for sarcopenia screening and diagnosis and application thereof Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to a marker group for screening and diagnosing sarcopenia and application thereof. Background Sarcopenia is an age-related muscle disorder characterized by progressive decline in skeletal muscle mass, strength and function, severely affecting the quality of life of the elderly, and increasing the risk of falls, fractures and deaths. Currently, international diagnostic standards (such as AWGS, EWGSOP 2) rely on dual energy X-ray absorption (DXA) to measure muscle mass, grip strength test, and pace assessment, which have the limitations of expensive equipment, cumbersome operation, difficulty in popularizing, and the like, and are not conducive to large-scale population screening. In recent years, plasma biomarkers have received attention for their advantage of non-invasive, reproducible collection. Studies have explored as potential markers, such as creatinine/cystatin C ratio, AST/ALT ratio, irisin, etc., but their diagnostic performance is generally poor (AUC < 0.8) and is vulnerable to co-morbid interference. In addition, the independent modeling of the proteome or the metabolome has the problems of high feature dimension, poor model generalization capability, insufficient verification and the like. Disclosure of Invention Aiming at the defects in the prior art, the invention provides a marker group for screening and diagnosing sarcopenia and application thereof. In order to achieve the above purpose, the technical scheme adopted by the invention for solving the technical problems is as follows: The invention aims to provide a marker group for sarcopenia screening and diagnosis, which is selected from at least four of the following proteins and metabolites, wherein the proteins comprise CXCL8, CCL13, IL18R1, RABGAP1L, CCL, FGF2 and CLEC4A; Metabolites include 1- (Cyclohexylmethyl) pro line (1- (cyclohexylmethyl) proline), 24-epi-brassinolide (table-24-brassinolide), 2- (3, 4, 5-Trimethoxyphenyl) -1H-benzimidazole (2- (3, 4, 5-trimethoxyphenyl) -1H-benzimidazole ）、2(1H)-Pyrimidinone, 5-[3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-、Propentofylline（3- methyl-1- (5-oxohexyl) -7-propylpurine-2, 6-dione), adenosine (adenosine), and (3-Oxo-2-piperaziyl) ACETIC ACID ((3-Oxo-2-piperazinyl) acetic acid (or 2- (3-oxopiperazin-1-yl) acetic acid)). Further, the marker panel consists of two proteins and two metabolites. Further, the marker panel consisted of CCL13, FGF2, fatty acid amide, and proline derivatives. Further, the proline derivative is 1- (cyclohexylmethyl) proline. Further, the marker set consisted of CXCL8、CCL13、IL18R1、RABGAP1L、CCL20、FGF2、CLEC4A、1-(Cyclohexylmethyl)proline、24-epi-brassinolide、2-(3,4,5-Trimethoxyphenyl)-1H-benzimidazole、2(1H)-Pyrimidinone, 5-[3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-、Propentofylline、Adenosine and (3-Oxo-2-piperazinyl) ACETIC ACID. It is another object of the present invention to provide a kit for screening and diagnosing sarcopenia, comprising a reagent for detecting the above marker set. It is another object of the present invention to provide the use of the reagent for detecting the above marker group in the preparation of a formulation for screening and diagnosing sarcopenia. Further, the preparation is a reagent, a kit or test paper. Further, the reagent includes a reagent for quantitatively detecting a protein antibody and a reagent for quantitatively detecting a metabolite. The invention has the beneficial effects that: The invention provides two myopathy high-sensitivity diagnosis combined models based on plasma multi-group combined machine learning. By Olink Explore 384 inflammatory proteome platform and LC-MS non-targeted metabolome technology, plasma samples of myopic patients and healthy controls were systematically analyzed to identify differentially expressed proteins and metabolites. And screening key features by adopting a plurality of machine learning algorithms, and constructing a single-group and double-group combined diagnosis model. A compact diagnostic model containing only four core biomarkers (CCL 13, FGF2, N-hexadecanoylpyrrolidine, 1- (cyclohexylmethyl) pro-line) was developed that exhibited excellent diagnostic performance (AUC > 0.9) in independent validation queues, with high clinical conversion value. Drawings FIG. 1 is a flow chart of the present invention; FIG. 2 is a volcanic plot of differential proteins and metabolites; FIG. 3 shows AUC detection results of six machine learning algorithms; FIG. 4 is a ROC curve of combined model 1 in the discovery and validation queue; Fig. 5 is a ROC curve for combined model 2 in the discovery and validation queue. Detailed Description The following description of the embodiments of the present invention is provided to facilitate understanding of the present invention b